SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting stellar 40-week Phase 3 results for sonelokimab, which investors and clinical experts are hailing as a new 'gold standard' for treating hidradenitis suppurativa. The community is buzzing with bullish sentiment as the data demonstrates deep tissue penetration and efficacy that rivals current market leaders, fueling intense speculation regarding a potential buyout or institutional accumulation as the company moves toward a BLA submission.

The Black Fish is a memecoin launched within the emerging “white whale/fishs” meta, which includes related projects such as White Whale, Black Whale, and White Fish. The project exists primarily as a cultural and narrative-driven token, drawing on contrast and symbolism within this broader meta rather than introducing novel blockchain technology or financial mechanisms.  The token does not claim intrinsic utility beyond its role as a meme-based digital asset. Its purpose is to participate in on-chain meme culture, community-driven storytelling, and speculative trading common to memecoins. The Black Fish positions itself as a smaller-scale counterpart within the ecosystem, emphasizing identity, aesthetics, and narrative consistency rather than technical innovation.  The project operates on a standard fungible token deployed on pumpfun, with market activity driven by open trading, community interest, and organic participation. No guarantees are made regarding value, performance, or long-term development, and the token is intended purely for entertainment and experimental participation within the memecoin space.

The Black Fish

The community is actively discussing building momentum and potential price action for BLACKFISH, with traders debating whether the current structure indicates an imminent rally or a speculative pump. Investors remain divided, weighing the prospect of early-stage growth against broader market caution regarding this low-cap asset.

PRIME is the native token of the Echelon Prime Foundation, a Web3 ecosystem advancing the next generation of gaming. Echelon creates and distributes tools to encourage innovation in, and promote the growth of, novel gaming models and economies. The first game to adopt and utilize PRIME is Parallel, a sci-fi trading card game.

Echelon Prime

Echelon Prime is trending as community members discuss a potential reversal and accumulation phase, with many focusing on its role in the growing Web3 gaming sector. Traders are actively debating the token's technical setup, with some anticipating a breakout driven by increased volume and broader interest in gaming-focused altcoins.

Solphin

Solphin is capturing attention as traders rotate capital from other popular aquatic-themed meme coins in search of the next major breakout. While some participants are actively accumulating the low-market-cap asset, the community is currently focused on technical issues with the stock's chart display and debating the sustainability of recent price volatility.

Kook Token is a personal, creator-driven streaming token built to revolutionize how people learn about crypto, gaming, and digital culture. Through engaging livestreams, real-talk podcasts, and interactive gameplays, it delivers a raw, unfiltered, and community-first learning experience. Kook Token makes education entertaining — no fluff, just real vibes, alpha drops, and pure fun. Whether you're a beginner or a degen, you'll feel right at home.

kook

KOOK is experiencing intense social media activity fueled by speculative momentum and community debate over its potential as a short-term trade compared to other altcoins in the sector. Traders remain polarized, with some actively calling for dips to be bought while others suggest rotating capital into newer meme coins due to high volatility.

Derpy dog on derp.trade 🐶| Long 🟢 and short 🔴 $DERPY with leverage up to 100X on derp.trade! https://app.derp.trade/coin/14bLBcB1iHUBGioLSwjbWBsP26nZKU16Qg44p5Vderp

Derpy

The community is debating the speculative nature of the token, with some traders praising its steady price movement and growth potential while others warn of volatility and risks common to memecoins. Investors are actively tracking its momentum alongside a basket of similar small-cap assets, highlighting a mix of cautious observation and bullish sentiment.

GODS token is the currency used in the blockchain-based online trading card game, Gods Unchained. The token will act as a governance so players will be able to decide the development direction of the game. Players can also use the token to mint rare cards. Most importantly, the GODS token will be an integral part of the play to earn concept of the game.

Gods Unchained

Gods Unchained is trending as the community speculates on a potential breakout driven by its play-to-earn ecosystem and integration with the Immutable X network. Investors are actively discussing its historical price movements and future growth potential within the gaming sector, with many focused on entry points and price recovery.

The KARRAT protocol is a decentralized gaming infrastructure layer, supported by $KARRAT and empowered by a truly decentralized community with a shared vision embracing gaming, entertainment and AI products catering for the new era.  To accelerate the evolution of gaming, entertainment, and AI-driven experiences with blockchain technology and a truly empowered community.  The KARRAT protocol pioneers a decentralized framework in gaming and entertainment, combining blockchain with community-driven collaboration. $KARRAT can animate ecosystems of games and products and the protocol makes tools available to support these industries and the adoption of KARRAT technology provides a unique, personalized gaming experience.

KARRAT

KARRAT is gaining significant attention from community members who are actively accumulating the token, citing strong partnerships with major tech and financial firms as key drivers for long-term potential in the Web3 gaming sector. While some participants are wary of volatility and token unlocking schedules, bulls remain focused on the project's infrastructure developments and the anticipation of a broader altcoin market recovery.

🌍 Introduction: A Legendary Icon, Reimagined for the Future The SEAMANIA Protocol, led by SEAMAN Cult, aims to revive one of SEGA Dreamcast's most iconic and best-selling game titles with AI integration—a worldwide cultural phenomenon that won numerous awards in the U.S. and Japan. More than just a game, SEAMAN was the world’s first AI-powered interactive experience, enabling voice-based conversations long before the AI revolution.    Now, SEAMAN returns not as a mere game, but as an advanced AI agent, blending nostalgia with cutting-edge technology. This human-faced fish is reborn as a deeply intelligent, emotionally responsiveAI, offering limitless customization and integration into the modern digital world.  With GenAI-powered customization, users can create their own SEAMAN AI, shaping it into a cherished lostone, a favorite celebrity, or even historical figures. This is no longer a game—it's an AI-driven personal companion and the digital evolution for human interaction.    🔥 Concept: The Wisdom of a Legendary AI-powered Companion At the core of the SEAMANIA Protocol lies the legendary Seaman—a mystical, human-faced fish endowed withancient wisdom and the ability to understand human language. More than just an AI, it is your trustedadvisor, best friend, therapist, personal cheerleader, witty conversationalist, intelligent guide, SEAMANIA is a life coach. Housed in your own digital aquarium, your SEAMAN AI reduces stress, combats loneliness, and guides humanity towards a brighter future. Imagine an AI companion that doesn’t just respond but truly understands, entertains, and supports you—blending humor, sarcasm, and wisdom.

SEAMANIA

SEAMANIA is trending as traders speculate on its potential to replicate the gains of previous meme coins, fueling intense discussions regarding its entry points and growth prospects. The community is actively debating whether to hold for further gains or capitalize on existing volatility, while many users express excitement about its low market capitalization and perceived momentum.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is currently trending due to investor reactions following its recent earnings report and guidance update, which have sparked intense community debate over future growth potential. Shareholders are actively discussing the company's long-term pivot toward QNX software for software-defined vehicles versus frustrations over stagnant revenue performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enliven Therapeutics (NASDAQ:ELVN) Given New $56.00 Price Target at HC Wainwright

HC Wainwright upped their price target on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a "buy" rating in a research report on Thursday...

Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High on Analyst Upgrade

Enliven Therapeutics (NASDAQ:ELVN) Sets New 12-Month High Following Analyst Upgrade...

<ul class="summary-bullets"><li>Enliven's ELVN-001 is a high-potential investigational therapy with a best-in-class profile, offering a complementary mechanism to the approaches of Novartis’s Asciminib and TERN-701, the analyst said.&nbsp;</li><li>Clear sees ELVN-001 as a lower-risk, high-upside asset.</li><li>The late-stage ENABLE-2 trial of ELVN-001 in second line and beyond CML remains on track for the second half of 2026 initiation.</li></ul>Shares of Enliven Therapeutics Inc (ELVN) rallied 15% on Wednesday after Wall Street highlighted that Merck's (MRK) $6.7 billion acquisition of Terns Pharmaceuticals' (TERN) TERN-701 underscores the unmet need and opportunity for safer, more effective chronic myeloid leukemia (CML) therapies, similar to the kind Enliven is developing.Clear Street noted the opportunity for CML therapies despite generics. The acquisition signals growing interest in CML beyond Novartis (NVS), it added. Chronic myeloid leukemia (CML) is a slow-growing blood cancer where the bone marrow produces too many myeloid cells.In this context, Enliven's ELVN-001 is a high-potential investigational therapy with a best-in-class profile, offering a complementary mechanism to the approaches of Novartis’s Asciminib and TERN-701 and multiple strategic paths to value, the firm argued.Clear sees ELVN-001 as a lower-risk, high-upside asset. The late-stage ENABLE-2 trial of ELVN-001 in second line and beyond CML remains on track for the second half of 2026 initiation, pending U.S. Food and Drug Administration’s alignment on dose selection and trial design.<h2 class="st-heading-2">Merck-Terns Deal</h2>Merck said earlier on Wednesday that it has entered into a definitive agreement to acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion in a bid to add TERN-701 to its portfolio. TERN-701 is an experimental therapy currently in development for certain patients with CML. The transaction is expected to close in the second quarter of 2026, the company said, but analysts including RBC Capital and William Blair noted that it expects another bidder to emerge for Terns.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ELVN stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/ELVN">ELVN stock</a> has gained 68% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/salesforce-reportedly-holding-back-on-raises-for-higher-level-employees/cZ3YDSyRISD">Salesforce Reportedly Holding Back On Raises For Higher-Level Employees</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Enliven Therapeutics, Inc. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio

According to Clear Street, the Terns-Merck deal underscores the unmet need and opportunity for safer, more effective chronic myeloid leukemia (CML) therapies.

Equity

According to Clear Street, the Terns-Merck deal underscores the unmet need and opportunity for safer, more effective chronic myeloid leukemia (CML) therapies.


Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up After Analyst Upgrade

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst Upgrade...

Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $45.00

Mizuho upped their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the company an "outperform" rating in a research note on Wednesday...

Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High - Should You Buy?

Enliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week High - Should You Buy...

Enliven Therapeutics (NASDAQ:ELVN) Trading 5.3% Higher - Here's What Happened

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 5.3% - Still a Buy...

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five analysts that are covering the firm, MarketBeat reports. One...

Enliven Therapeutics, Inc. $ELVN Shares Bought by HighVista Strategies LLC

HighVista Strategies LLC grew its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 83.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The...

Enliven Therapeutics (NASDAQ:ELVN) CFO Sells 10,000 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 10,000 shares of the company's stock in a transaction that occurred on Friday, March 6th. The shares were sold at an...

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Enliven Therapeutics Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

ELVN
Enliven Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ELVN News

ELVNEnliven Therapeutics Inc